A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice

There is an ongoing need to develop strategic combinations of therapeutic agents to prevent type 1 diabetes (T1D) or to preserve islet β-cell mass in new-onset disease. Although clinical trials using candidate therapeutics are commonly based on preclinical studies, concern is growing regarding the r...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Diabetes
Huvudupphovsmän: Gill, Ronald G., Pagni, Philippe P., Kupfer, Tinalyn, Wasserfall, Clive H., Deng, Songyan, Posgai, Amanda, Manenkova, Yulia, Bel Hani, Amira, Straub, Laura, Bernstein, Philip, Atkinson, Mark A., Herold, Kevan C., von Herrath, Matthias, Staeva, Teodora, Ehlers, Mario R., Nepom, Gerald T.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Diabetes Association 2016
Ämnen:
Immunology and Transplantation
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5860426/
https://ncbi.nlm.nih.gov/pubmed/26718498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db15-0492
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk